| Literature DB >> 30923539 |
Qi Hua1,2, Li Fan1,2, Jing Li1,2.
Abstract
Entities:
Year: 2019 PMID: 30923539 PMCID: PMC6431598 DOI: 10.11909/j.issn.1671-5411.2019.02.001
Source DB: PubMed Journal: J Geriatr Cardiol ISSN: 1671-5411 Impact factor: 3.327
Class of recommendations.
| Classes of recommendations | Definitions | Suggested wording to use |
| Class I | Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective. | Is recommended/is indicated. |
| Class II | Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure. | |
| Class IIa | Weight of evidence/opinion is in favor of usefulness/efficacy. | Should be considered. |
| Class IIb | Usefulness/efficacy is less well established by evidence/opinion. | May be considered. |
| Class III | Evidence or general agreement that the given treatment or procedure is not useful/effective, and in some cases may be harmful. | Is not recommended. |
Levels of evidences.
| Level of evidence A | Data derived from multiple randomized clinical trials or meta-analyses. |
| Level of evidence B | Data derived from a single randomized clinical trial or large non-randomized studies. |
| Level of evidence C | Consensus of opinion of the experts and/or small studies, retrospective studies, registries. |
Categories of BP and definitions of hypertension grade in the elderly.[1]
| Categories | SBP, mmHg | DBP, mmHg | |
| Optimal | < 120 | and | < 80 |
| High Normal | 120–139 | and (or) | 80–89 |
| Hypertension | ≥ 140 | and (or) | ≥ 90 |
| Grade 1 hypertension | 140–159 | and (or) | 90–99 |
| Grade 2 hypertension | 160–179 | and (or) | 100–109 |
| Grade 3 hypertension | ≥ 180 | and (or) | ≥ 110 |
| Isolated systolic hypertension | ≥ 140 | and | < 90 |
BP category is defined by the highest level of BP, whether systolic or diastolic. Isolated systolic hypertension is graded according to SBP values. BP: blood pressure; DBP: diastolic blood pressure; SBP: systolic blood pressure.
Prevalence, awareness rate, treated rate, controlled rate, the results of two surveys in China.
| Year | Age | Prevalence | Awareness rate | Treatment rate | Control rate |
| 2002 | ≥ 60 | 49.1% | 37.6% | 32.2% | 7.6% |
| 2012–2015 | ≥ 60 | 53.2% | 57.1% | 51.4% | 18.2% |
Risk categories of hypertension in elderly patients.
| Other risk factors and medical history | Level of BP | ||
| Grade 1 | Grade 2 | Grade 3 | |
| 1–2 risk factors | Moderate | Moderate | Very high |
| ≥ 3 risk factors or TODs or diabetic mellitus | High | High | Very high |
| Concomitant clinical situation | Very high | Very high | Very high |
BP: blood pressure; TODs: target organ damages.
FRAIL scale.[47]
| No. | Items | Questions |
| 1 | Fatigue | You feel tired all or most of the time during the past four weeks. |
| 2 | Resistance | By yourself and not using aids, you have difficulty walking up one stair without resting. |
| 3 | Ambulation | By yourself and not using aids, you have difficulty walking one block or 100 m. |
| 4 | Illness | A doctor has told you that you have more than five illnesses. The illnesses include hypertension, diabetes, cancer (other than a micro-dermal carcinoma), chronic lung disease, heart attack, congestive heart failure, angina, asthma, arthritis, stroke, and kidney disease. |
| 5 | Loss of weight | Weight loss ≥ 5% occurs in one year or less. |
Frail: ≥ 3 items; pre-frail: 1–3 items; robust: 0 item.
Fried frailty assessment.[45]
| No. | Items | Male | Female |
| 1 | Loss of weight | Unintentional weight loss [10 Ibs (4.5 kg) or > 5%] in past year | |
| 2 | Walking time, 4.57 m | Height ≤ 173 cm: ≥ 7 s | Height ≤ 159 cm: ≥ 7 s |
| Height > 173 cm: ≥ 6 s | Height >159 cm: ≥ 6 s | ||
| 3 | Grip strength, kg | BMI ≤ 24.0 kg/m2 ≤ 29 | BMI ≤ 23.0 kg/m2: ≤ 17 |
| BMI 24.1–26.0 kg/m2: ≤ 30 | BMI 23.1–26.0 kg/m2: ≤ 17.3 | ||
| BMI 26.1–28.0 kg/m2: ≤ 30 | BMI 26.1–29.0 kg/m2: ≤ 18 | ||
| BMI > 28.0 kg/m2: ≤ 32 | BMI > 29.0 kg/m2: ≤ 21 | ||
| 4 | Physical activity (MLTA) | < 383 kcal/week (walk about 2.5 h) | < 270 kcal/week (Walk about 2 h) |
| 5 | Exhaustion | Any item in CES-D scored 2–3. | |
| How many days have you experienced in the past week? | |||
| (1) I felt that doing all the things need efforts. | |||
| (2) I could not get going. | |||
| Scored 0: < 1 d; Scored 1: 1–2 d; Scored 2: ≥ 3–4 d; Scored 3: < 4 d. | |||
Patients with 3–5, 1–2, and 0 factors are classified as frail, pre-frail, and robust, respectively. BMI: body mass index; CES-D: Center for Epidemiologic Studies-Depression questionnaire; MLTA: Minnesota leisure time activity.
Recommendation for BP thresholds for treatment and targets of BP.
| Recommendation | Class | Level |
| Initiation of BP-lowering drug treatment is recommended for patients aged ≥ 65 years and BP ≥ 140/90 mmHg, simultaneous with the initiation of lifestyle changes, | I | A |
| Initiation of BP-lowering drug treatment should be considered for patients aged ≥ 80 years and BP ≥ 150/90 mmHg, | IIa | B |
| Provided that the treatment is well tolerated, BP target should be 140/90 mmHg or lower. | ||
| If the very old patients with hypertension are classified as frail, BP ≥ 160/90 mmHg, the drug treatment should be initiated, SBP values should be targeted to 150 mmHg or lower, but ≥ 130 mmHg as possible. | IIa | C |
| Discontinuing treatment if the treatment is well tolerated is not recommended. | III | A |
BP: blood pressure; SBP: systolic blood pressure.
Commonly used antihypertensive drugs.
| Types | Drugs | Daily dose, mg/d | Times per day | Precautions |
| Thiazide/Thiazide-like diuretics | Chlorthalidone | 6.25–25 | 1 | Sodium, potassium, uric acid and calcium concentrations should be monitored. |
| Indapamide | 0.625–2.5 | 1 | Use cautiously if the patient has a history of gout, unless the patient has received uric acid lowering therapy. | |
| Loop diuretics | Bumetanide | 0.5–4 | 2 | For patients with symptomatic heart failure, loop diuretics are preferred. |
| Furosemide | 20–80 | 1–2 | For patients with CKD stage 3–4, loop diuretics are preferred. | |
| Torasemide | 5–10 | 1 | ||
| Potassium-sparing diuretics | Amiloride | 5–10 | 1–2 | The antihypertensive effect of single use was not obvious. |
| Triamterene | 25–100 | 1–2 | Avoid these drugs in patients with CKD stage 5. | |
| Aldosterone antagonists | Eplerenone | 50–100 | 1–2 | Spironolactone increases the risk of breast hyperplasia and ED in men compared with eplerenone. |
| Spironolactone | 20–60 | 1–3 | Avoid the combination with potassium supplements and potassium sparing drugs. | |
| Avoid these drugs in patients with CKD stage 3–4. | ||||
| CCB (Dihydropyridine) | Amlodipine besylate | 2.5–10 | 1 | No absolute contraindication. |
| Levamlodipine maleate | 1.25–5 | 1 | ||
| Levamlodipine besylate | 1.25–5 | 1 | ||
| Felodipine | 2.5–10 | 1 | ||
| Lercanidipine | 10–20 | 1 | ||
| Nifedipine delayed-release tablets | 10–80 | 2 | ||
| Nifedipine controlled released tablets | 30–60 | 1 | ||
| Lacidipine | 4–8 | 1 | ||
| Cinidipine | 5–10 | 1 | ||
| Benidipine | 4–8 | 1 | ||
| CCB (Non-dihydropyridine) | Diltiazem | 90–180 | 2–3 | Avoid routine combination with beta blockers for the potential of bradycardia and conduction block. |
| Diltiazem sustained release tablets | 90–360 | 1–2 | ||
| Verapamil sustained release tablets | 120–240 | 1–2 | ||
| ACEI | Benazepril | 5–40 | 1–2 | The combination of ACEI and ARB is not recommended. |
| Captopril | 25–300 | 2–3 | ||
| Enalapril | 2.5–40 | 1–2 | ||
| Fosinopril | 10–40 | 1 | ||
| Lisinopril | 2.5–40 | 1 | ||
| Imidapril | 2.5–10 | 1 | ||
| Perindopril | 4–8 | 1 | ||
| Ramipril | 1.25–20 | 1 | ||
| ARB | Candesartan | 4–32 | 1 | Indications and contraindications as same as ACEI. |
| Irbesartan | 150–300 | 1 | ||
| Losartan | 25–100 | 1 | ||
| Olmesartan | 20–40 | 1 | ||
| Telmisartan | 20–80 | 1 | ||
| Valsartan | 80–160 | 1 | ||
| Allisartan | 240 | 1 | ||
| Cardio-selective beta blockers | Atenolol | 12.5–50 | 1–2 | β-blockers are contraindicated in patients with disease of bronchospasm. |
| Bisoprolol | 2.5–10 | 1 | ||
| Metoprolol tartrate | 25–100 | 2 | ||
| Metoprolol succinate | 23.75–190 | 1 | ||
| Non-selective beta blockers (mixed Alpha + Beta blockers) | Carvedilol | 12.5–50 | 2 | Beta blockers are contraindicated in patients with disease of bronchospasm. |
| Aronixil | 10–20 | 1–2 | ||
| Labetalol | 200–600 | 2 | ||
| α1-receptor antagonism | Doxazosin | 1–16 | 1 | Those drugs may cause postural hypotension, particularly in the elderly patients. |
| Prazosin | 1–10 | 2–3 | ||
| Terazosin | 1–20 | 1–2 | ||
| Centrally active drugs | Clonidine | 0.1–0.8 | 2–3 | Avoid abrupt withdrawal in case of hypertensive crisis. |
| Methyldopa | 250–1000 | 2–3 | ||
| Reserpine | 0.05–0.25 | 1 | ||
| Direct vasodilator | Hydralazine | 25–100 | 2 | High dose may cause hirsutism and lupus syndrome. |
ACEI: angiotensin-converting-enzyme inhibitor; ARB: angiotensin receptor blocker; CCB: calcium channel blocker; CKD: chronic kidney disease; ED: erectile dysfunction.
Preferred drugs in certain clinical condition.
| Clinical conditions | Drugs |
| Asymptomatic TOD | |
| LVH | ACEI, CCB, ARB |
| Asymptomatic atherosclerosis | ACEI, CCB, ARB |
| Microalbuminuria | ACEI, ARB |
| Mild renal insufficiency | ACEI, ARB |
| Clinical cardiovascular events | |
| Previous myocardial infarction | BB, ACEI, ARB |
| Angina pectoris | BB, CCB |
| Heart failure | Diuretics, BB, ACEI, ARB, Aldosterone antagonist |
| Aortic aneurysm | BB |
| AF, prevention | ACEI, ARB, BB, Aldosterone antagonist |
| AF, ventricular rate control | BB, non-dihydropyridine CCB |
| Peripheral arterial diseases | ACEI, CCB, ARB |
| Other | |
| Isolated systolic hypertension (elderly) | Diuretics, CCB |
| Metabolic syndrome | ACEI, ARB, CCB |
| Diabetes | ACEI, ARB |
ACEI: angiotensin-converting-enzyme inhibitor; AF: atrial fibrillation; ARB: Angiotensin receptor blocker; BB: β-blocker; CCB: Calcium channel blocker; LVH: left ventricular hypertrophy; TOD: target organ damage.
Selection of antihypertensive dugs for the elderly patients.
| Recommendation | Class | Level |
| Thiazide/thiazide-like diuretics, CCB, ACEI and ARB are recommended for the initiation and maintenance of antihypertension therapy. | I | A |
| For most elderly patients with more than 20 mmHg above the target BP, a combination of two drugs is recommended as the initial treatment. | I | A |
| If the BP target is still not achieved, the combination of thiazide/ thiazide-like diuretic, CCB and ACEI/ARB is recommended, or single-pill combination is also recommended. | I | A |
| Drug therapy for very old patients aged over 80 years and frail elderly patients is recommended start with low dose monotherapy. | I | A |
| The combination of two RAS inhibitor is not recommended. | III | A |
ACEI: angiotensin-converting-enzyme inhibitor; ARB: angiotensin receptor blocker; CCB: calcium channel blocker; RAS: renin-angiotensin system.
Treatment strategies for elderly hypertensive patients with cerebrovascular disease.
| Recommendation | Class | Level |
| For patients with acute cerebral hemorrhage, SBP should be lowered to < 180 mmHg. | IIa | B |
| In patients with acute ischemic stroke, lowering BP to < 200 mmHg is reasonable. | IIa | C |
| In order to prevent recurrence of stroke and other vascular events, patients with acute ischemic stroke or TIA who had been treated with antihypertensive drugs for a long time in the past are recommended to resume antihypertensive therapy several days after the onset of the event. | I | A |
| The BP target of patients with history of ischemic stroke or TIA should be determined considering the specific circumstances. It is reasonable that BP should be lowered below 140/90 mmHg. | IIa | B |
| It is reasonable to lower the BP below 150/90 mmHg in elderly patients. | IIa | C |
BP: blood pressure; SBP: systolic blood pressure; TIA: transient ischemic attack.
Treatment strategies for elderly hypertensive patients with coronary artery disease.
| Recommendation | Class | Level |
| For patients aged < 80 years, it is recommended to target BP to < 140/90 mmHg. | I | A |
| If the body condition is good and the patient could tolerate the antihypertensive therapy, especially for those with previous myocardial infarction, the BP can be lowered to < 130/80 mmHg. | IIa | B |
| For patients aged ≥ 80 years, the target of BP should be < 150/90 mmHg. If tolerated, the BP should be further lowered to less than 140/90 mmHg. | IIa | B |
| For those with increased pulse pressure (≥ 60 mmHg), it is emphasized that the SBP should achieve the target value. When DBP < 60 mmHg, SBP should be lowered to target value gradually with carefully monitoring. | IIa | C |
BP: blood pressure; SBP: systolic blood pressure.
Therapeutic strategies for treatment of hypertension with the elderly with heart failure.
| Recommendation | Class | Level |
| In elderly hypertensive patients with heart failure, BP should be controlled at < 140/90 mmHg first and further lowered to < 130/80 mmHg. | IIa | B |
| If there is no contraindications, ACEI or ARB, aldosterone antagonist, diuretics, beta blockers, angiotensin receptor enkephalin inhibitor are recommended. | I | A |
| Non-dihydropyridine calcium channel blockers (verapamil and diltiazem) are not recommended. | III | C |
ACEI: angiotensin-converting-enzyme inhibitor; ARB: angiotensin receptor blocker; BP: blood pressure.
Treatment strategies for elderly hypertensive patients with CKD.
| Recommendation | Class | Level |
| The BP in elderly patients with CKD is recommended to be lowered to < 140/90 mmHg. | I | A |
| If the urinary protein is 30–300 mg/d or more, BP is recommended to be reduced to < 130/80 mmHg. | I | C |
| The SBP of hemodialysis patients should be less than 160 mmHg before dialysis, and the target of BP in elderly peritoneal dialysis patients can be extended to < 150/90 mmHg. | IIa | C |
BP: blood pressure; CKD: chronic kidney disease; SBP: systolic blood pressure.
Recommendation of antihypertensive drugs for elderly hypertensive patients with CKD.
| Recommendation | Class | Level |
| ACEI or ARB is recommended for CKD patients, especially for patients with proteinuria. | I | A |
| Initiating at a low dose, ACEI or ARB may be used to the maximum dose | IIb | C |
| When ACEI or ARB is used, the initial dose of CKD3–4 patients should be reduced by half. Serum potassium and creatinine levels as well as eGFR should be carefully monitored. The dosage as well as the form of drugs should be adjusted in time. | IIa | C |
| It is not recommended that ACEI/ARB be used together. | III | A |
| CCB is recommended for hypertensive patients with obvious renal dysfunction and salt sensitivity. | I | C |
| For CKD patients with volume overload, loop diuretics (such as furosemide) are recommended for CKD4 or CKD5. | I | C |
| Alpha/beta receptor blockers may be considered to be used in combination antihypertensive therapy for patients with resistant hypertension and are not easily cleared by dialysis. | IIb | C |
ACEI: angiotensin-converting-enzyme inhibitor; ARB: angiotensin receptor blocker; CCB: calcium channel blocker; CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate.
Treatment strategies for elderly hypertensive patients with diabetes mellitus.
| Recommendation | Class | Level |
| The BP of elderly diabetic patients is recommended to be controlled < 140/90 mmHg, if tolerated, the target is recommended to be < 130/80 mmHg. | I | A |
| DBP is recommended to be no less than 70 mmHg. | I | C |
BP: blood pressure; DBP: diastolic blood pressure.
Recommendation of antihypertensive drugs for elderly hypertensive patients with diabetes mellitus.
| Recommendation | Class | Level |
| ACEI/ARB is the first choice for patients with hypertension and diabetes mellitus. When ACEI is intolerable, ARB is recommended. | I | A |
| If the patients have diabetic nephropathy, especially those with UACR > 300 mg/g or eGFR < 60 mL · min−1 · (1.73 m2)−1, ACEI | I | A |
| Dihydropyridine CCBs combined with ACEI or ARB are recommended for diabetic patients. | I | B |
| Loop diuretics | IIb | C |
| Large dose of diuretics is not recommended. | III | C |
| Beta blocker is not the first choice for diabetes mellitus patients.When necessary, low dose and hyper-selective beta1 blocker combined with ACEI or ARB may be considered. | IIb | C |
| The combination of beta blockers and diuretics is not recommended. | III | C |
| Elderly patients with prostatic hypertrophy may consider the use of alpha blockers, but the risk of orthostatic hypotension may be considered. | IIb | C |
ACEI: angiotensin-converting-enzyme inhibitor; ARB: angiotensin receptor blocker; CCB: calcium channel blocker; CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; UACR: urinary albumin-to-creatinine ratio.
Treatment strategies for elderly patients with resistant hypertension.
| Recommendation | Class | Level |
| It is recommended to eliminate factors affecting BP control, actively improve lifestyle and improve compliance. | I | B |
| If the target BP is not achieved, aldosterone antagonists should be considered. | IIa | B |
| β-blocker is recommended in patients with coronary heart disease or heart failure if the resting heart rate is high. | I | A |
| Alpha-1 beta receptor blockers | IIa | B |
| Adding direct vasodilators (such as hydralazine, minoxidil) or central antihypertensive drugs (such as clonidine and alpha-methyldopa) may be considered for elderly patients with resistant hypertension. | IIb | B |
BP: blood pressure; GFR: glomerular filtration rate.
Specification, targets and drug selection for treatment of hypertension emergencies.
| Clinical presentations | Specification | Goal | Drug types and dosage | Class | Level |
| Hypertensive encephalopathy. | Brain perfusion should be guaranteed while lowering BP. SBP should be reduced by 20%–25% within one hour after drug administration, but no more than 50%. | 160–180/100–110 mmHg | Urapidil (10–50 mg | I | C |
| Cerebral hemorrhage. | When SBP is more than 220 mmHg in patients with acute cerebral hemorrhage, active intravenous antihypertensive treatment is needed while the BP should be closely monitored. When SBP is more than 180 mmHg, intravenous antihypertensive treatment should be adjusted and guided by clinical manifestations. | SBP < 180 mmHg | Urapidil (10–50 mg | IIa | B |
| Subarachnoid hemorrhage. | Prevent exacerbation of hemorrhage and excessive decrease of BP, which may cause transient neurological deficits and delayed diffuse lethal cerebral vasospasm. | SBP < 150–160 mmHg | Nicardipine (0.5–10 µg/kg/min | I | C |
| Cerebral infarction. | Generally no need for tight control of BP, slightly higher BP is beneficial to perfusion of ischemic area, unless BP ≥ 200/110 mmHg or with heart failure, aortic dissection, hypertensive encephaloathy, | Reduce BP by no more than 25% in 24 h | Urapidil (10–50 mg | IIa | B |
| Malignant hypertension with or without renal damage. | Avoid violent fluctuation of BP, steadily reduce BP and ensuring renal perfusion. | < 140/90 mmHg | Diuretics | I | C |
| Acute heart failure. | It is often manifested as acute pulmonary edema. In order to relieve symptoms and reduce congestion, vasodilators combined with diuretics are recommended. | < 140/90 mmHg | Sodium nitroprusside (0.25–10 µg/kg/min | I | C |
| Acute coronary syndrome. | Reduce BP and reduce oxygen consumption of myocardium, but should not affect coronary perfusion pressure and coronary blood flow, prevent reflex tachycardia. | < 140/90 mmHg | Nitroglycerine (5–100 µg/min | I | C |
| Aortic dissection. | Dilate blood vessels, control heart rate, depress myocardium contraction, rapidly reduce and maintain BP at the lowest possible level on the premise of ensuring organ perfusion; beta-blocker and non-dihydropyridine calcium channel blocker are preferred for intravenous treatment, other drugs, such us urapidil, sodium nitroprusside, nicardipine | SBP < 120 mmHg | Esmolol (250–500 µg/kg | I | C |
BP: blood pressure; SBP: systolic blood pressure.
Recommendation for the management of elderly patients with hypertension and AF.
| Recommendation | Class | Level |
| Short-term electrocardiogram and subsequent continuous electrocardiogram monitoring for at least 72 h are recommended for patients with TIA or ischemic stroke. | I | B |
| Patient with atrial fibrillation, especially those undergoing anticoagulation therapy should control BP to < 140/90 mmHg. | IIa | B |
| ARB and ACEI are recommended for antihypertensive therapy to prevent new AF and recurrence of paroxysmal AF. | I | B |
| All patients with CHA2DS2-VASc ≥ 2 points for males and ≥ 3 points for females) are recommended to take oral anticoagulants for anticoagulation therapy. | I | A |
| Radiofrequency ablation is recommended for patients with symptomatic paroxysmal AF whose pharmacological therapy is ineffective. | I | A |
| Radiofrequency ablation should be considered for patients with symptomatic long-term persistent AF whose pharmacological therapy is ineffective. | IIa | C |
ACEI: angiotensin-converting-enzyme inhibitor; AF: atrial fibrillation; ARB: angiotensin receptor blocker; BP: blood pressure.
Recommendation for perioperative management of hypertension in the elderly.
| Recommendation | Class | Level |
| For elective surgery, it is recommended to postpone the operation of patients with SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg. | IIa | C |
| The perioperative BP control target of elderly patients with hypertension should be less than 150/90 mmHg. If diabetes mellitus or chronic nephropathy exists and the drug is well tolerated, the BP should be further reduced to less than 140/90 mmHg. | IIa | C |
| In addition to the absolute value requirement of BP, perioperative BP fluctuation should not exceed 10% of the baseline. | IIa | C |
| For those who take beta blockers chronically, it is not recommended to interrupt the use of beta blockers before operation. | III | B |
| Elderly patients taking ACEI or ARB should be discontinued before non-cardiac surgery. | IIa | C |
ACEI: angiotensin-converting-enzyme inhibitor; ARB: angiotensin receptor blocker; BP: blood pressure; DBP: diastolic blood pressure; SBP: systolic blood pressure.
Recommended drugs for the treatment of OH.
| Drugs | Drug category | Dose | Side effects | Precautions |
| Midodrine | α receptor agonist | Recommended dose: 2.5–10 mg, TID. | Purpura, urinary retention, and lying hypertension. | Its use 4–5 h before sleep should be avoided. |
| Droxidopa | Precursor substance of norepinephrine | Initial dose: 100 mg, TID, and dose escalation of 100 mg every other 3–7 d until appropriate maintenance dose. | Lying hypertension, headache, dizziness, and nausea. | It should be carefully used in patients with congestive heart failure and chronic renal insufficiency. |
| Fludrocortisone | Effects of adrenal mineralocorticoid receptors | Generally, the initial dose is 0.1 mg with being less than 0.3 mg every day. | Lying hypertension, edema, hypokalemia, headache, and adrenal function inhibition may occur in severe cases. | It should be forbidden in patients with heart failure, kidney failure, or severe hypertension. |
Recommendation for the frailty assessment of hypertension in the elderly.
| Recommendation | Class | Level |
| Frailty should be assessed before the antihypertensive treatment for elderly hypertensive patients, in order to assess the benefits and risks of antihypertensive treatment, | I | B |